AbbVie Expects Peak Sales of $7 Billion for Imbruvica
AbbVie (ABBV) has projected Imbruvica’s annual revenues to reach $5 billion by 2020. The drug has already changed the treatment paradigm in the second line plus CLL segment and for CLL patients with 17p deletion. AbbVie expects that in the future, nearly eight out of ten CLL patients will benefit from an Imbruvica-based therapy at one point or another.